UAE-based Globalpharma, a wholly owned subsidiary of Dubai Investments, has announced the launch of its first herbal medicine manufacturing line.
The line, approved by the Ministry of Health & Prevention (MOHAP) will produce MG21 in collaboration with Al Fujairah Healing.
MG21 is an herbal anti-inflammatory medicine consisting of a composition of herbs like Myrrh and Costus, used for the treatment and prevention of respiratory infections, indigestion, skin infections, headaches and diabetic conditions.
Al Fujairah Healing Company selected Globalpharma to develop, sell, market, promote and distribute MG21 across the Middle East, a statement said.
The facility at the Globalpharma premises in Dubai Investments Park is expected to yield an annual production capacity of around half million capsules.
Mohammed Saeed Al Raqbani, general manager of Dubai Investment Industries said: “Globalpharma aims to progress into a globally attractive and technologically driven integrated healthcare enterprise, focused on continually innovating and adapting to deliver the best in healthcare.
“We are pleased to add the MG21 herbal medicine to our existing line-up of medicines and to locally produce it at our fully GMP compliant facility. Embarking on this exciting journey with Al Fujairah Healing Company, we believe that this herbal medicine will not only become a popular product with consumers, but also help strengthen the UAE’s position as a leader in pharmaceuticals in the region.”
Basem AlBarahmeh, general manager of Globalpharma added: “Globalpharma has already signed a distribution agreement with Alphamed, one of the leading local suppliers in the country, with the aim of securing availability of MG21 in the majority of pharmacies before the end of this year.”
Follow us on
